Literature DB >> 9353349

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

L H Wong1, K G Krauer, I Hatzinisiriou, M J Estcourt, P Hersey, N D Tam, S Edmondson, R J Devenish, S J Ralph.   

Abstract

The mechanism of IFN resistance was examined in three long-term cell lines, SK-MEL-28, SK-MEL-3, and MM96, exhibiting significant variation in responsiveness to the antiproliferative and antiviral effects of type I IFNs. The JAK-STAT components involved in IFN signal transduction were analyzed in detail. After exposure to IFN, activation of the IFN type I receptor-linked tyrosine kinases, JAK-1 and TYK-2, was detected at similar levels in both IFN-sensitive and IFN-resistant cell types, indicating that IFN resistance did not result from a deficiency in signaling at the level of receptor-associated kinase activation. However, analysis of ISGF3 transcription factor components, STAT1, STAT2, and p48-ISGF3gamma, revealed that their expression and activation correlated with cellular IFN responsiveness. The analysis was extended to also include IFN-sensitive primary melanocytes, three additional IFN-resistant melanoma cell lines, and seven cell cultures recently established from melanoma patient biopsies. It was consistently observed that the most marked difference in ISGF3 was a lack of STAT1 in the resistant versus the sensitive cells. Transfection of the IFN-resistant MM96 cell line to express increased levels of STAT1 protein partially restored IFN responsiveness in an antiviral assay. We conclude that a defect in the level of STAT1 and possibly all three ISGF3 components in IFN-resistant human melanoma cells may be a general phenomenon responsible for reduced cellular responsiveness of melanomas to IFNs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353349     DOI: 10.1074/jbc.272.45.28779

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways.

Authors:  C V Ramana; N Grammatikakis; M Chernov; H Nguyen; K C Goh; B R Williams; G R Stark
Journal:  EMBO J       Date:  2000-01-17       Impact factor: 11.598

Review 2.  The interferon signaling network and transcription factor C/EBP-beta.

Authors:  Hui Li; Padmaja Gade; Weihua Xiao; Dhan V Kalvakolanu
Journal:  Cell Mol Immunol       Date:  2007-12       Impact factor: 11.530

Review 3.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

4.  IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha.

Authors:  Takaya Tsuno; Josef Mejido; Tongmao Zhao; Hana Schmeisser; Angel Morrow; Kathryn C Zoon
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.456

5.  Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.

Authors:  Diana L Thomas; Rosalinda Doty; Vesna Tosic; Jia Liu; David M Kranz; Grant McFadden; Amy L Macneill; Edward J Roy
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

6.  Vesicular stomatitis virus as a treatment for colorectal cancer.

Authors:  J H Stewart; M Ahmed; S A Northrup; M Willingham; D S Lyles
Journal:  Cancer Gene Ther       Date:  2011-09-02       Impact factor: 5.987

7.  A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon.

Authors:  Maria D Gainey; Mary J Manuse; Griffith D Parks
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.

Authors:  Patricia Devaux; Gregory Hodge; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

9.  Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

Authors:  Megan Moerdyk-Schauwecker; Nirav R Shah; Andrea M Murphy; Eric Hastie; Pinku Mukherjee; Valery Z Grdzelishvili
Journal:  Virology       Date:  2012-12-14       Impact factor: 3.616

10.  Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus.

Authors:  Brooke L Carey; Maryam Ahmed; Shelby Puckett; Douglas S Lyles
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.